Literature DB >> 19560402

Urethral ratio on voiding cystourethrogram: a comparative method to assess success of posterior urethral valve ablation.

Rahul K Gupta1, Hemanshi S Shah, Vinay Jadhav, Abhaya Gupta, Advait Prakash, Bejal Sanghvi, Sandesh V Parelkar.   

Abstract

OBJECTIVE: To develop a simple, objective and reproducible quantitative measurement to assess success of posterior urethral valve ablation.
METHOD: In 30 patients with posterior urethral valves the diagnosis was confirmed by voiding cystourethrogram (VCUG). Our protocol was to perform valve ablation, and repeat VCUG at 12 weeks postoperatively. Urethral ratio was calculated by dividing the posterior urethral diameter by the anterior urethral diameter. Thirty males undergoing VCUG for urinary tract infections were evaluated as normative controls.
RESULTS: Median age of controls was 12 months (2 days-6 years) and of study group was 13 months (1 day-11 years). Mean urethral ratio in pre-fulguration group was 4.94 (+/-2.97) and in post-fulguration group was 2.134 (+/-1.19) (P<0.001). The mean urethral ratio in the control group of 1.73 (+/-0.577) was significantly different from the pre-fulguration group result (P<0.001), but not significantly different in comparison to the post-fulguration group (P=0.104).
CONCLUSION: Calculation of urethral ratio on VCUG as a method of assessment of outcome of fulguration is objective, reproducible, and allows preoperative and postoperative VCUG from different facilities to be compared. A post-fulguration urethral ratio of 2.5-3 represents an acceptable result postoperatively.

Entities:  

Mesh:

Year:  2009        PMID: 19560402     DOI: 10.1016/j.jpurol.2009.05.009

Source DB:  PubMed          Journal:  J Pediatr Urol        ISSN: 1477-5131            Impact factor:   1.830


  7 in total

Review 1.  All grown up: A transitional care perspective on the patient with posterior urethral valves.

Authors:  Melise A Keays; Kristen Mcalpine; Blayne Welk
Journal:  Can Urol Assoc J       Date:  2018-04       Impact factor: 1.862

2.  The changes of urethral morphology recognized in voiding cystourethrography after endoscopic transurethral incision for posterior urethral valve in boys with intractable daytime urinary incontinence and nocturnal enuresis.

Authors:  Taiju Hyuga; Shigeru Nakamura; Shina Kawai; Taro Kubo; Rieko Furukawa; Toshinori Aihara; Makiko Mieno; Hideo Nakai
Journal:  World J Urol       Date:  2017-02-28       Impact factor: 4.226

3.  Can the posterior:anterior urethral ratio on voiding cystourethrogram be used as a reliable predictor of successful posterior urethral valve ablation in male children?

Authors:  Zakiyah Gaibie; Nasreen Mahomed; Karen L Petersen; Glenda Moonsamy; Akram A H Bokhari; Ahmed Adam
Journal:  SA J Radiol       Date:  2020-06-09

4.  Which patients are at higher risk for residual valves after posterior urethral valve ablation?

Authors:  Mehdi Shirazi; Mohamadreza Farsiani; Mohammad Natami; Kiomars Izadpanah; Amir Malekahmadi; Abbasali Khakbaz
Journal:  Korean J Urol       Date:  2014-01-15

5.  Posterior urethral valves: Morphological normalization of posterior urethra after fulguration is a significant factor in prognosis.

Authors:  Prema Menon; K L N Rao; S Vijaymahantesh; R P Kanojia; R Samujh; Y K Batra; K S Sodhi; A K Saxena; A Bhattacharya; B R Mittal
Journal:  J Indian Assoc Pediatr Surg       Date:  2010-07

6.  Correlation of Urethral Ratio and Bladder Wall Thickness with Cystoscopic Findings in Posterior Urethral Valve Patients to Assess Residual Valves.

Authors:  Tanmay Motiwala; Arvind Sinha; Kirtikumar J Rathod; Vivek Manchanda; Taruna Yadav; Avinash Jadhav; Manish Pathak; Rahul Saxena
Journal:  J Indian Assoc Pediatr Surg       Date:  2022-01-11

7.  Evaluation of surgical procedures of mouse urethra by visualization and the formation of fistula.

Authors:  Taiju Hyuga; Daiki Hashimoto; Daisuke Matsumaru; Shinji Kumegawa; Shinichi Asamura; Kentaro Suzuki; Kei-Ichi Katayama; Shigeru Nakamura; Hideo Nakai; Gen Yamada
Journal:  Sci Rep       Date:  2020-10-26       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.